Search

Your search keyword '"Hassel, Jessica C"' showing total 602 results
Start Over Author "Hassel, Jessica C" Publication Type Academic Journals
602 results on '"Hassel, Jessica C"'

6. Preferences of physicians for treatment-related toxicity vs. recurrence in melanoma (GERMELATOX-A): the doctors’ perspective

Author

Kähler, Katharina C., Gutzmer, Ralf, Angela, Yenny, Livingstone, Elisabeth, Lodde, Georg, Meiss, Frank, Rafei-Shamsabadi, David A., Weyer-Fahlbusch, Sera S., Nashan, Dorothée, Loquai, Carmen, Hassel, Jessica C., Sachse, Michael M. M., Maul, Lara V., Heinzerling, Lucie, Heppt, Markus V., Colapietro, Chiara, Rusch, Judith, and Blome, Christine

Published
2024
Full Text
View/download PDF

7. Liver-directed treatment is associated with improved survival and increased response to immune checkpoint blockade in metastatic uveal melanoma: results from a retrospective multicenter trial

Author

Koch, Elias A. T., Petzold, Anne, Wessely, Anja, Dippel, Edgar, Eckstein, Markus, Gesierich, Anja, Gutzmer, Ralf, Hassel, Jessica C., Knorr, Harald, Kreuzberg, Nicole, Leiter, Ulrike, Loquai, Carmen, Meier, Friedegund, Meissner, Markus, Mohr, Peter, Pföhler, Claudia, Rahimi, Farnaz, Schadendorf, Dirk, Schlaak, Max, Thoms, Kai-Martin, Ugurel, Selma, Utikal, Jochen, Weichenthal, Michael, Schuler-Thurner, Beatrice, Berking, Carola, and Heppt, Markus V.

Published
2023
Full Text
View/download PDF

10. Checkpoint inhibitor–induced lichen planus differs from spontaneous lichen planus on the clinical, histological, and gene expression level

Author

Meier-Schiesser, Barbara, Zecha, Christine, Zierold, Sarah, Kolm, Isabel, Röckel, Magdalena, Fröhlich, Waltraud, Mittag, Nora, Schmitt, Christina, Kumbrink, Joerg, Hassel, Jessica C., Berking, Carola, Nashan, Dorothee, French, Lars Einar, Vera-González, Julio, Dummer, Reinhard, Kerl-French, Katrin, and Heinzerling, Lucie

Published
2024
Full Text
View/download PDF

12. Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma

Author

Albrecht, Lea Jessica, Dimitriou, Florentia, Grover, Piyush, Hassel, Jessica C., Erdmann, Michael, Forschner, Andrea, Johnson, Douglas B., Váraljai, Renáta, Lodde, Georg, Placke, Jan Malte, Krefting, Frederik, Zaremba, Anne, Ugurel, Selma, Roesch, Alexander, Schulz, Carsten, Berking, Carola, Pöttgen, Christoph, Menzies, Alexander M., Long, Georgina V., Dummer, Reinhard, Livingstone, Elisabeth, Schadendorf, Dirk, and Zimmer, Lisa

Published
2024
Full Text
View/download PDF

13. Association of antibiotic treatment with survival outcomes in treatment-naïve melanoma patients receiving immune checkpoint blockade

Author

Chorti, Eleftheria, Kowall, Bernd, Hassel, Jessica C., Schilling, Bastian, Sachse, Michael, Gutzmer, Ralf, Loquai, Carmen, Kähler, Katharina C., Hüsing, Anika, Gilde, Catharina, Thielmann, Carl M., Zaremba-Montenari, Anne, Placke, Jan-Malte, Gratsias, Emmanouil, Martaki, Anna, Roesch, Alexander, Ugurel, Selma, Schadendorf, Dirk, Livingstone, Elisabeth, Stang, Andreas, and Zimmer, Lisa

Published
2024
Full Text
View/download PDF

19. Adjuvant immunotherapy with nivolumab versus observation in completely resected Merkel cell carcinoma (ADMEC-O): disease-free survival results from a randomised, open-label, phase 2 trial

Author

van Akkooi, Alexander, van Houdt, Winan, Wilhelm, Tabea, Farmer, Kimberley, Ulrich, Claas, Gambichler, Thilo, Bluhm, Leonie, Schinagl, Heidemarie, Kellner, Ivonne, Herbst, Rudolf, Meiß, Frank, Rafei-Shamsabadi, David, Sell, Sabine, Kaatz, Martin, Wulfken, Lena, Hartmann, Martin, Kähler, Katharina, Ziemer, Mirjana, Simon, Jan, Terheyden, Patrick, Thaci, Diamant, Loquai, Carmen, Mitzel-Rink, Heidrun, Grabbe, Stephan, Stege, Henner, Gaiser, Maria, Utikal, Jochen, Berking, Carola, Heinzerling, Lucie, Schlaak, Max, Tomsitz, Dirk, Dyballa, Jörg, Magnolo, Nina, Weishaupt, Carsten, Berneburg, Mark, Garbe, Claus, Flatz, Lukas, Gesierich, Anja, Schilling, Bastian, Becker, Jürgen C, Ugurel, Selma, Leiter, Ulrike, Meier, Friedegund, Gutzmer, Ralf, Haferkamp, Sebastian, Zimmer, Lisa, Livingstone, Elisabeth, Eigentler, Thomas K, Hauschild, Axel, Kiecker, Felix, Hassel, Jessica C, Mohr, Peter, Fluck, Michael, Thomas, Ioannis, Garzarolli, Marlene, Grimmelmann, Imke, Drexler, Konstantin, Spillner, Alexandra N, Eckhardt, Sebastian, and Schadendorf, Dirk

Published
2023
Full Text
View/download PDF

21. Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial

Author

Carvajal, Richard D., Butler, Marcus O., Shoushtari, Alexander N., Hassel, Jessica C., Ikeguchi, Alexandra, Hernandez-Aya, Leonel, Nathan, Paul, Hamid, Omid, Piulats, Josep M., Rioth, Matthew, Johnson, Douglas B., Luke, Jason J., Espinosa, Enrique, Leyvraz, Serge, Collins, Laura, Goodall, Howard M., Ranade, Koustubh, Holland, Chris, Abdullah, Shaad E., Sacco, Joseph J., and Sato, Takami

Published
2022
Full Text
View/download PDF

23. Cytokine release syndrome-like serum responses after COVID-19 vaccination are frequent and clinically inapparent under cancer immunotherapy

Author

Walle, Thomas, Bajaj, Sunanjay, Kraske, Joscha A., Rösner, Thomas, Cussigh, Christiane S., Kälber, Katharina A., Müller, Lisa Jasmin, Strobel, Sophia Boyoung, Burghaus, Jana, Kallenberger, Stefan M., Stein-Thöringer, Christoph K., Jenzer, Maximilian, Schubert, Antonia, Kahle, Steffen, Williams, Anja, Hoyler, Birgit, Zielske, Lin, Skatula, Renate, Sawall, Stefanie, Leber, Mathias F., Kunes, Russell Z., Krisam, Johannes, Fremd, Carlo, Schneeweiss, Andreas, Krauss, Jürgen, Apostolidis, Leonidas, Berger, Anne Katrin, Haag, Georg M., Zschäbitz, Stefanie, Halama, Niels, Springfeld, Christoph, Kirsten, Romy, Hassel, Jessica C., Jäger, Dirk, and Ungerechts, Guy

Published
2022
Full Text
View/download PDF

25. Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study

Author

Müller-Jensen, Leonie, Zierold, Sarah, Versluis, Judith M., Boehmerle, Wolfgang, Huehnchen, Petra, Endres, Matthias, Mohr, Raphael, Compter, Annette, Blank, Christian U., Hagenacker, Tim, Meier, Friedegund, Reinhardt, Lydia, Gesierich, Anja, Salzmann, Martin, Hassel, Jessica C., Ugurel, Selma, Zimmer, Lisa, Banks, Patricia, Spain, Lavinia, Soon, Jennifer A., Enokida, Tomohiro, Tahara, Makoto, Kähler, Katharina C., Seggewiss-Bernhardt, Ruth, Harvey, Catriona, Long, Georgina V., Schöberl, Florian, von Baumgarten, Louisa, Hundsberger, Thomas, Schlaak, Max, French, Lars E., Knauss, Samuel, and Heinzerling, Lucie M.

Published
2022
Full Text
View/download PDF

26. Adjuvant nivolumab plus ipilimumab or nivolumab alone versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): final results of a randomised, double-blind, phase 2 trial

Author

Livingstone, Elisabeth, Zimmer, Lisa, Hassel, Jessica C, Fluck, Michael, Eigentler, Thomas K, Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kiecker, Felix, Dippel, Edgar, Roesch, Alexander, Ziemer, Mirjana, Conrad, Beate, Körner, Silvia, Simon, Jan-Christoph, Herbst, Rudolf A, Berking, Carola, Utikal, Jochen, Sell, Sabine, Martens, Uwe M, Terheyden, Patrick, Stadler, Rudolf, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C, and Schadendorf, Dirk

Published
2022
Full Text
View/download PDF

29. Bimodal intensity-modulated radiotherapy in combination with carbon ion therapy (C12) of mucosal melanomas - data of the last decade from Heidelberg University Hospital.

Author

Bauer, Lukas, Paul, Angela, Regnery, Sebastian, Deng, Maximilian Y., Ellerbrock, Malte, Mielke, Thomas, Harrabi, Semi B., Seidensaal, Katharina, Held, Thomas, Herfarth, Klaus, Debus, Jürgen, Hassel, Jessica C., and Uzun-Lang, Kristin

Subjects
HEAVY ion radiotherapy, TREATMENT effectiveness, INTENSITY modulated radiotherapy, PROGRESSION-free survival, RADIODERMATITIS
Abstract

Introduction: Due to the rarity of mucosal melanomas, few recent studies can be found investigating the success and side effects of therapy for this entity with large numbers of patients. In this retrospective analysis, the efficacy and toxicity of combined intensity-modulated radiotherapy (IMRT) and carbon ion therapy (C12) of mucosal melanomas were analyzed to contribute to a better understanding of this rare disease. Methods: Twenty-two patients were included from 2013 to 2022 in the Department of Radiation Oncology at Heidelberg University Hospital. 19 patients received bimodal radiotherapy consisting of radiotherapy by IMRT and carbon ion therapy (C12). 3 patients received photon only IMRT. In addition to Overall Survival (OS), local control rate (LCR), locoregional control rate (LRCR) and progression-free survival (PFS), early and late toxicity of treatment was analyzed. Bimodal radiotherapy consisted of IMRT of the primary tumor region and cervical lymph nodes in a single dose of 2 Gy up to the dose of 50.0 Gy in the basic schedule after application of a C12 boost of the primary tumor region up to 24 Gy (RBE) in a single dose of 3 Gy (RBE) up to the total dose of 74.0 Gy (RBE) in 5-6 fractions/week. Photon only radiotherapy comprised IMRT up to total doses of 66-70,4 Gy in 5 fractions/week. Results: After 2 years, overall survival, progression-free survival, local control and locoregional control were 46%, 41%, 77% and 77%, respectively. 4 out of 5 patients with local relapse showed in-field recurrence inside the C12 boost volume. The primary tumor in these patients was always located in the main nasal cavity and/or paranasal sinus. Leading acute toxicity was grade 2 mucositis (12 patients, 55%) followed by grade 1 radiation dermatitis (10 patients, 45%). The cumulative incidence of late grade 3 toxicities was 15%. Discussion: The combination of IMRT with carbon ion therapy in the treatment of mucosal melanoma provides promising local control rates with mild acute toxicity despite unfavorable patient preselection. The unfavorable overall survival as well as progression-free survival rates indicate that concomitant systemic therapies should be the subject of future research. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

30. Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial

Author

Larkin, James, Minor, David, D'Angelo, Sandra, Neyns, Bart, Smylie, Michael, Miller, Wilson H, Gutzmer, Ralf, Linette, Gerald, Chmielowski, Bartosz, Lao, Christopher D, Lorigan, Paul, Grossmann, Kenneth, Hassel, Jessica C, Sznol, Mario, Daud, Adil, Sosman, Jeffrey, Khushalani, Nikhil, Schadendorf, Dirk, Hoeller, Christoph, Walker, Dana, Kong, George, Horak, Christine, and Weber, Jeffrey

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Immunology, Minority Health, Clinical Trials and Supportive Activities, Cancer, Health Disparities, Clinical Research, 6.1 Pharmaceuticals, Administration, Intravenous, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Immunological, Antineoplastic Combined Chemotherapy Protocols, Carboplatin, Dacarbazine, Disease Progression, Drug Administration Schedule, Female, Humans, Male, Melanoma, Middle Aged, Nivolumab, Paclitaxel, Progression-Free Survival, Skin Neoplasms, Time Factors, Young Adult, Oncology & Carcinogenesis, Oncology and carcinogenesis
Abstract

Purpose Until recently, limited options existed for patients with advanced melanoma who experienced disease progression while receiving treatment with ipilimumab. Here, we report the coprimary overall survival (OS) end point of CheckMate 037, which has previously shown that nivolumab resulted in more patients achieving an objective response compared with chemotherapy regimens in ipilimumab-refractory patients with advanced melanoma. Patients and Methods Patients were stratified by programmed death-ligand 1 expression, BRAF status, and best prior cytotoxic T-lymphocyte antigen-4 therapy response, then randomly assigned 2:1 to nivolumab 3 mg/kg intravenously every 2 weeks or investigator's choice chemotherapy (ICC; dacarbazine 1,000 mg/m2 every 3 weeks or carboplatin area under the curve 6 plus paclitaxel 175 mg/m2 every 3 weeks). Patients were treated until they experienced progression or unacceptable toxicity, with follow-up of approximately 2 years. Results Two hundred seventy-two patients were randomly assigned to nivolumab (99% treated) and 133 to ICC (77% treated). More nivolumab-treated patients had brain metastases (20% v 14%) and increased lactate dehydrogenase levels (52% v 38%) at baseline; 41% of patients treated with ICC versus 11% of patients treated with nivolumab received anti-programmed death 1 agents after randomly assigned therapy. Median OS was 16 months for nivolumab versus 14 months for ICC (hazard ratio, 0.95; 95.54% CI, 0.73 to 1.24); median progression-free survival was 3.1 months versus 3.7 months, respectively (hazard ratio, 1.0; 95.1% CI, 0.78 to 1.436). Overall response rate (27% v 10%) and median duration of response (32 months v 13 months) were notably higher for nivolumab versus ICC. Fewer grade 3 and 4 treatment-related adverse events were observed in patients on nivolumab (14% v 34%). Conclusion Nivolumab demonstrated higher, more durable responses but no difference in survival compared with ICC. OS should be interpreted with caution as it was likely impacted by an increased dropout rate before treatment, which led to crossover therapy in the ICC group, and by an increased proportion of patients in the nivolumab group with poor prognostic factors.

Published
2018

32. Clinical characteristics and therapy response in unresectable melanoma patients stage IIIB-IIID with in-transit and satellite metastases

Author

Zaremba, Anne, Philip, Manuel, Hassel, Jessica C., Glutsch, Valerie, Fiocco, Zeno, Loquai, Carmen, Rafei-Shamsabadi, David, Gutzmer, Ralf, Utikal, Jochen, Haferkamp, Sebastian, Reinhardt, Lydia, Kähler, Katharina C., Weishaupt, Carsten, Moreira, Alvaro, Thoms, Kai-Martin, Wilhelm, Tabea, Pföhler, Claudia, Roesch, Alexander, Ugurel, Selma, Zimmer, Lisa, Stadtler, Nadine, Sucker, Antje, Kiecker, Felix, Heinzerling, Lucie, Meier, Friedegund, Meiss, Frank, Schlaak, Max, Schilling, Bastian, Horn, Susanne, Schadendorf, Dirk, and Livingstone, Elisabeth

Published
2021
Full Text
View/download PDF

34. Sustainable responses in metastatic melanoma patients with and without brain metastases after elective discontinuation of anti-PD1-based immunotherapy due to complete response

Author

Dimitriou, Florentia, Zaremba, Anne, Allayous, Clara, Kähler, Katharina C., Gerard, Camille L., Festino, Lucia, Schäfer, Sarah, Toussaint, Frédéric, Heinzerling, Lucie, Hassel, Jessica C., Ascierto, Paolo A., Michielin, Olivier, Hauschild, Axel, Lebbe, Céleste, Livingstone, Elisabeth, Ramelyte, Egle, Cheng, Phil F., Dummer, Reinhard, and Mangana, Joanna

Published
2021
Full Text
View/download PDF

35. Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Dermatooncology Group

Author

Grimmelmann, Imke, Momma, Michael, Zimmer, Lisa, Hassel, Jessica C., Heinzerling, Lucie, Pföhler, Claudia, Loquai, Carmen, Ruini, Cristel, Utikal, Jochen, Thoms, Kai-Martin, Kähler, Katharina C., Eigentler, Thomas, Herbst, Rudolf A., Meier, Friedegund, Debus, Dirk, Berking, Carola, Kochanek, Corinna, Ugurel, Selma, and Gutzmer, Ralf

Published
2021
Full Text
View/download PDF

36. Outcome of melanoma patients with elevated LDH treated with first-line targeted therapy or PD-1-based immune checkpoint inhibition

Author

Knispel, Sarah, Gassenmaier, Maximilian, Menzies, Alexander M., Loquai, Carmen, Johnson, Douglas B., Franklin, Cindy, Gutzmer, Ralf, Hassel, Jessica C., Weishaupt, Carsten, Eigentler, Thomas, Schilling, Bastian, Schummer, Patrick, Sirokay, Judith, Kiecker, Felix, Owen, Carina N., Fleischer, Maria I., Cann, Christopher, Kähler, Katharina C., Mohr, Peter, Bluhm, Leonie, Niebel, Dennis, Thoms, Kai-Martin, Goldinger, Simone M., Reinhardt, Lydia, Meier, Friedegund, Berking, Carola, Reinhard, Raphael, Susok, Laura, Ascierto, Paolo A., Drexler, Konstantin, Pföhler, Claudia, Tietze, Julia, Heinzerling, Lucie, Livingstone, Elisabeth, Ugurel, Selma, Long, Georgina V., Stang, Andreas, Schadendorf, Dirk, and Zimmer, Lisa

Published
2021
Full Text
View/download PDF

37. Hematological immune related adverse events after treatment with immune checkpoint inhibitors

Author

Kramer, Rafaela, Zaremba, Anne, Moreira, Alvaro, Ugurel, Selma, Johnson, Douglas B., Hassel, Jessica C., Salzmann, Martin, Gesierich, Anja, Weppler, Alison, Spain, Lavinia, Loquai, Carmen, Dudda, Milena, Pföhler, Claudia, Hepner, Adriana, Long, Georgina V., Menzies, Alexander M., Carlino, Matteo S., Sachse, Michael M., Lebbé, Céleste, Baroudjian, Barouyr, Enokida, Tomohiro, Tahara, Makoto, Schlaak, Max, Hayani, Kinan, Bröckelmann, Paul J., Meier, Friedegund, Reinhardt, Lydia, Friedlander, Philip, Eigentler, Thomas, Kähler, Katharina C., Berking, Carola, Zimmer, Lisa, and Heinzerling, Lucie

Published
2021
Full Text
View/download PDF

39. Immune Checkpoints and Cellular Landscape of the Tumor Microenvironment in Non-Melanoma Skin Cancer (NMSC).

Author

Mousa, Ahmed M., Enk, Alexander H., Hassel, Jessica C., and Reschke, Robin

Subjects
MYELOID-derived suppressor cells, REGULATORY T cells, IMMUNE checkpoint proteins, BASAL cell carcinoma, TUMOR-infiltrating immune cells
Abstract

Non-melanoma skin cancer (NMSC) is primarily categorized into basal cell carcinoma (BCC), the most prevalent form of skin cancer, and cutaneous squamous cell carcinoma (cSCC), the second most common type. Both BCC and cSCC represent a significant health burden, particularly in immunocompromised individuals and the elderly. The immune system plays a pivotal role in the development and progression of NMSC, making it a critical focus for therapeutic interventions. This review highlights key immunological targets in BCC and cSCC, with a focus on immune checkpoint molecules such as PD-1/PD-L1 and CTLA-4, which regulate T cell activity and contribute to immune evasion. This review also highlights anti-tumor immune cell subsets within the tumor microenvironment (TME), such as tumor-infiltrating lymphocytes (TILs) and dendritic cells. Additionally, it examines the immunosuppressive elements of the TME, including regulatory T cells (Tregs), myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and cancer-associated fibroblasts (CAFs), as well as their roles in NMSC progression and resistance to therapy. Emerging strategies targeting these immune elements, such as monoclonal antibodies, are also discussed for their potential to enhance anti-tumor immune responses and improve clinical outcomes. By elucidating the immunological landscape of BCC and cSCC and drawing comparisons to melanoma, this review highlights the transformative potential of immunotherapy in treating these malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

40. T Cell-Engaging Bispecific Antibodies Targeting gp100 and PRAME: Expanding Application from Uveal Melanoma to Cutaneous Melanoma.

Author

Reschke, Robin, Enk, Alexander H., and Hassel, Jessica C.

Subjects
BISPECIFIC antibodies, TESTICULAR cancer, CELL-mediated cytotoxicity, CHIMERIC proteins, MELANOMA, T cells
Abstract

Uveal melanoma represents a rare and aggressive subtype of melanoma with limited treatment options and poor prognosis, especially in the metastatic setting. Tebentafusp, a bispecific fusion protein, offers a promising therapeutic approach by targeting gp100, an antigen highly expressed in uveal melanoma cells, and redirecting T cell-mediated cytotoxicity towards tumor cells. This review provides an overview of the preclinical and clinical data on tebentafusp in the management of metastatic uveal melanoma. We summarize the mechanism of action, clinical efficacy, safety profile, and ongoing research efforts surrounding this innovative immunotherapy. Preclinical studies have demonstrated the ability of tebentafusp to induce potent and specific anti-tumor immune responses against gp100-expressing uveal melanoma cells. Clinical trials have shown encouraging results, with tebentafusp exhibiting meaningful clinical activity in a subset of patients with metastatic uveal melanoma. Importantly, tebentafusp has also demonstrated a manageable safety profile. By specifically targeting tumor cells expressing gp100, tebentafusp offers a promising therapeutic avenue for individuals with metastatic uveal melanoma, meeting a significant clinical need in this context. Continued clinical trials will provide additional insights into the impact of tebentafusp on treatment-resistant metastatic cutaneous melanoma. Furthermore, we are exploring the potential of T cell engagers directed against the cancer testis antigen PRAME, which could have widespread utility in the treatment of cutaneous melanoma as well as other PRAME-expressing malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

43. IL4I1 Is a Metabolic Immune Checkpoint that Activates the AHR and Promotes Tumor Progression

Author

Sadik, Ahmed, Somarribas Patterson, Luis F., Öztürk, Selcen, Mohapatra, Soumya R., Panitz, Verena, Secker, Philipp F., Pfänder, Pauline, Loth, Stefanie, Salem, Heba, Prentzell, Mirja Tamara, Berdel, Bianca, Iskar, Murat, Faessler, Erik, Reuter, Friederike, Kirst, Isabelle, Kalter, Verena, Foerster, Kathrin I., Jäger, Evelyn, Guevara, Carina Ramallo, Sobeh, Mansour, Hielscher, Thomas, Poschet, Gernot, Reinhardt, Annekathrin, Hassel, Jessica C., Zapatka, Marc, Hahn, Udo, von Deimling, Andreas, Hopf, Carsten, Schlichting, Rita, Escher, Beate I., Burhenne, Jürgen, Haefeli, Walter E., Ishaque, Naveed, Böhme, Alexander, Schäuble, Sascha, Thedieck, Kathrin, Trump, Saskia, Seiffert, Martina, and Opitz, Christiane A.

Published
2020
Full Text
View/download PDF

45. Adjuvant nivolumab plus ipilimumab or nivolumab monotherapy versus placebo in patients with resected stage IV melanoma with no evidence of disease (IMMUNED): a randomised, double-blind, placebo-controlled, phase 2 trial

Author

Berking, Carola, Herbst, Rudolf A, Martens, Uwe M, Sell, Sabine, Stadler, Rudolf, Terheyden, Patrick, Utikal, Jochen, Zimmer, Lisa, Livingstone, Elisabeth, Hassel, Jessica C, Fluck, Michael, Eigentler, Thomas, Loquai, Carmen, Haferkamp, Sebastian, Gutzmer, Ralf, Meier, Friedegund, Mohr, Peter, Hauschild, Axel, Schilling, Bastian, Menzer, Christian, Kieker, Felix, Dippel, Edgar, Rösch, Alexander, Simon, Jan-Christoph, Conrad, Beate, Körner, Silvia, Windemuth-Kieselbach, Christine, Schwarz, Leonora, Garbe, Claus, Becker, Jürgen C, and Schadendorf, Dirk

Published
2020
Full Text
View/download PDF

46. An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma

Author

Sahin, Ugur, Oehm, Petra, Derhovanessian, Evelyna, Jabulowsky, Robert A., Vormehr, Mathias, Gold, Maike, Maurus, Daniel, Schwarck-Kokarakis, Doreen, Kuhn, Andreas N., Omokoko, Tana, Kranz, Lena M., Diken, Mustafa, Kreiter, Sebastian, Haas, Heinrich, Attig, Sebastian, Rae, Richard, Cuk, Katarina, Kemmer-Brück, Alexandra, Breitkreuz, Andrea, Tolliver, Claudia, Caspar, Janina, Quinkhardt, Juliane, Hebich, Lisa, Stein, Malte, Hohberger, Alexander, Vogler, Isabel, Liebig, Inga, Renken, Stephanie, Sikorski, Julian, Leierer, Melanie, Müller, Verena, Mitzel-Rink, Heidrun, Miederer, Matthias, Huber, Christoph, Grabbe, Stephan, Utikal, Jochen, Pinter, Andreas, Kaufmann, Roland, Hassel, Jessica C., Loquai, Carmen, and Türeci, Özlem

Published
2020
Full Text
View/download PDF

50. Impact of radiation, systemic therapy and treatment sequencing on survival of patients with melanoma brain metastases

Author

Rauschenberg, Ricarda, Bruns, Johannes, Brütting, Julia, Daubner, Dirk, Lohaus, Fabian, Zimmer, Lisa, Forschner, Andrea, Zips, Daniel, Hassel, Jessica C., Berking, Carola, Kaehler, Katharina C., Utikal, Jochen, Gutzmer, Ralf, Terheyden, Patrik, Meiss, Frank, Rafei-Shamsabadi, David, Kiecker, Felix, Debus, Dirk, Dabrowski, Evelyn, Arnold, Andreas, Garzarolli, Marlene, Kuske, Marvin, Beissert, Stefan, Löck, Steffen, Linn, Jennifer, Troost, Esther G.C., and Meier, Friedegund

Published
2019
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results